These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 36190973)
1. Trial protocol of an open label pilot study of lisdexamfetamine for the treatment of acute methamphetamine withdrawal. Acheson LS; Ezard N; Lintzeris N; Dunlop A; Brett J; Rodgers C; Gill A; Christmass M; McKetin R; Farrell M; Shoptaw S; Siefried KJ PLoS One; 2022; 17(10):e0275371. PubMed ID: 36190973 [TBL] [Abstract][Full Text] [Related]
2. Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot feasibility and safety trial. Acheson LS; Ezard N; Lintzeris N; Dunlop A; Brett J; Rodgers C; Gill A; Christmass M; McKetin R; Farrell M; Shoptaw S; Siefried KJ Drug Alcohol Depend; 2022 Dec; 241():109692. PubMed ID: 36399936 [TBL] [Abstract][Full Text] [Related]
3. LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence. Ezard N; Dunlop A; Hall M; Ali R; McKetin R; Bruno R; Phung N; Carr A; White J; Clifford B; Liu Z; Shanahan M; Dolan K; Baker AL; Lintzeris N BMJ Open; 2018 Jul; 8(7):e020723. PubMed ID: 30030312 [TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study. Ezard N; Clifford B; Dunlop A; Bruno R; Carr A; Liu Z; Siefried KJ; Lintzeris N BMJ Open; 2021 May; 11(5):e044696. PubMed ID: 34006547 [TBL] [Abstract][Full Text] [Related]
5. Study protocol: a dose-escalating, phase-2 study of oral lisdexamfetamine in adults with methamphetamine dependence. Ezard N; Dunlop A; Clifford B; Bruno R; Carr A; Bissaker A; Lintzeris N BMC Psychiatry; 2016 Dec; 16(1):428. PubMed ID: 27905916 [TBL] [Abstract][Full Text] [Related]
6. A pilot randomised controlled trial of modafinil during acute methamphetamine withdrawal: feasibility, tolerability and clinical outcomes. Lee N; Pennay A; Hester R; McKetin R; Nielsen S; Ferris J Drug Alcohol Rev; 2013 Jan; 32(1):88-95. PubMed ID: 22630616 [TBL] [Abstract][Full Text] [Related]
7. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design. Coghill DR; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson CS; Civil R; Dauphin M; Higgins N; Lyne A; Gasior M; Squires LA J Am Acad Child Adolesc Psychiatry; 2014 Jun; 53(6):647-657.e1. PubMed ID: 24839883 [TBL] [Abstract][Full Text] [Related]
8. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder. Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198 [TBL] [Abstract][Full Text] [Related]
9. A Long-Term, Open-Label Safety and Tolerability Study of Lisdexamfetamine Dimesylate in Children Aged 4-5 Years with Attention-Deficit/Hyperactivity Disorder. Childress AC; Lloyd E; Johnson SA; Gunawardhana L; Arnold V J Child Adolesc Psychopharmacol; 2022 Mar; 32(2):98-106. PubMed ID: 35230142 [No Abstract] [Full Text] [Related]
10. Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study. Babcock T; Dirks B; Adeyi B; Scheckner B BMC Pharmacol Toxicol; 2012 Dec; 13():18. PubMed ID: 23254273 [TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder. Banaschewski T; Johnson M; Lecendreux M; Zuddas A; Adeyi B; Hodgkins P; Squires LA; Coghill DR CNS Drugs; 2014 Dec; 28(12):1191-203. PubMed ID: 25139785 [TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, placebo-controlled, crossover study of the effects of lisdexamfetamine dimesylate and mixed amphetamine salts on cognition throughout the day in adults with attention-deficit/hyperactivity disorder. Martin PT; Corcoran M; Zhang P; Katic A Clin Drug Investig; 2014 Feb; 34(2):147-57. PubMed ID: 24297663 [TBL] [Abstract][Full Text] [Related]
13. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design. Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921 [TBL] [Abstract][Full Text] [Related]
14. Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe. Coghill DR; Banaschewski T; Nagy P; Otero IH; Soutullo C; Yan B; Caballero B; Zuddas A CNS Drugs; 2017 Jul; 31(7):625-638. PubMed ID: 28667569 [TBL] [Abstract][Full Text] [Related]
15. Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder. Childress AC; Findling RL; Wu J; Kollins SH; Wang Y; Martin P; Robertson B J Child Adolesc Psychopharmacol; 2020 Apr; 30(3):128-136. PubMed ID: 32233956 [No Abstract] [Full Text] [Related]
16. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults. Najib J Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715 [TBL] [Abstract][Full Text] [Related]
17. A study protocol for the N-ICE trial: A randomised double-blind placebo-controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for methamphetamine ("ice") dependence. McKetin R; Dean OM; Turner A; Kelly PJ; Quinn B; Lubman DI; Dietze P; Carter G; Higgs P; Baker AL; Sinclair B; Reid D; Manning V; Te Pas N; Liang W; Thomas T; Bathish R; Kent M; Raftery D; Arunogiri S; Cordaro F; Hill H; Berk M Trials; 2019 Jun; 20(1):325. PubMed ID: 31164169 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial. Hudson JI; McElroy SL; Ferreira-Cornwell MC; Radewonuk J; Gasior M JAMA Psychiatry; 2017 Sep; 74(9):903-910. PubMed ID: 28700805 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study. Boellner SW; Stark JG; Krishnan S; Zhang Y Clin Ther; 2010 Feb; 32(2):252-64. PubMed ID: 20206783 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Biederman J; Krishnan S; Zhang Y; McGough JJ; Findling RL Clin Ther; 2007 Mar; 29(3):450-63. PubMed ID: 17577466 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]